A randomized, double-blind, placebo-controlled, ascending, single-dose study of a human monoclonal anti-FGF23 antibody (KRN23) in X-linked hypophosphatemia
Carpenter T, Imel E, Ruppe M, Weber T, Klausner M, Wooddell M, Kawakami T, Ito T, Zhang X, Humphrey J, Insogna K, Peacock M. A randomized, double-blind, placebo-controlled, ascending, single-dose study of a human monoclonal anti-FGF23 antibody (KRN23) in X-linked hypophosphatemia. Bone Abstracts 2014 DOI: 10.1530/boneabs.3.pp90.Peer-Reviewed Original Research